Clinuvel Pharmaceuticals Ltd Total Assets
Clinuvel Pharmaceuticals Ltd total assets. Based on the latest financial reports, Clinuvel Pharmaceuticals Ltd (CUV) holds total assets worth AU$269.70 Million AUD (≈ $190.83 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see CUV market cap for the company's overall valuation and market capitalisation.
Total Assets of Clinuvel Pharmaceuticals Ltd (2000–2025)
Total assets of Clinuvel Pharmaceuticals Ltd from 2000 to 2025. This chart illustrates how Clinuvel Pharmaceuticals Ltd's total assets have evolved over time, based on quarterly financial data. See latest Clinuvel Pharmaceuticals Ltd stock price today for real-time trading data and today's change.
Clinuvel Pharmaceuticals Ltd - Asset Composition Analysis
Clinuvel Pharmaceuticals Ltd Total Assets Breakdown (June 2025)
Clinuvel Pharmaceuticals Ltd total assets breakdown as of June 2025. Clinuvel Pharmaceuticals Ltd's total assets of AU$269.70 Million consist of 96.8% current assets and 3.2% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 82.5% |
| Accounts Receivable | AU$27.46 Million | 10.1% |
| Inventory | AU$8.82 Million | 3.3% |
| Property, Plant & Equipment | AU$7.13 Million | 2.6% |
| Intangible Assets | AU$185.03K | 0.1% |
| Goodwill | AU$185.03K | 0.1% |
Asset Composition Trend (2000–2025)
This chart illustrates how Clinuvel Pharmaceuticals Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore CUV current assets to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Clinuvel Pharmaceuticals Ltd's current assets represent 96.8% of total assets in 2025, an increase from 51.8% in 2000.
- Cash Position: Cash and equivalents constituted 82.5% of total assets in 2025, up from 51.3% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 47.0% in 2000.
- Asset Diversification: The largest asset category is accounts receivable at 10.1% of total assets.
Clinuvel Pharmaceuticals Ltd Competitors by Total Assets
Key competitors of Clinuvel Pharmaceuticals Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
Clinuvel Pharmaceuticals Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 14.64 | 17.37 | 9.35 |
| Quick Ratio | 14.17 | 16.65 | 9.20 |
| Cash Ratio | 2.02 | 1.28 | 8.49 |
| Working Capital | AU$243.53 Million | AU$214.46 Million | AU$71.70 Million |
Clinuvel Pharmaceuticals Ltd - Advanced Valuation Insights
This section examines the relationship between Clinuvel Pharmaceuticals Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.93 |
| Latest Market Cap to Assets Ratio | 0.93 |
| Asset Growth Rate (YoY) | 17.6% |
| Total Assets | AU$271.75 Million |
| Market Capitalization | $252.62 Million USD |
Valuation Analysis
Near Book Valuation: The market values Clinuvel Pharmaceuticals Ltd's assets close to their book value (0.93x), suggesting investors view the company's assets at approximately fair value.
Rapid Asset Growth: Clinuvel Pharmaceuticals Ltd's assets grew by 17.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Clinuvel Pharmaceuticals Ltd (2000–2025)
The table below shows the annual total assets of Clinuvel Pharmaceuticals Ltd from 2000 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | AU$271.75 Million ≈ $192.28 Million |
+17.58% |
| 2024-06-30 | AU$231.12 Million ≈ $163.53 Million |
+18.81% |
| 2023-06-30 | AU$194.52 Million ≈ $137.64 Million |
+34.33% |
| 2022-06-30 | AU$144.81 Million ≈ $102.47 Million |
+33.39% |
| 2021-06-30 | AU$108.57 Million ≈ $76.82 Million |
+33.14% |
| 2020-06-30 | AU$81.54 Million ≈ $57.70 Million |
+30.79% |
| 2019-06-30 | AU$62.35 Million ≈ $44.11 Million |
+45.31% |
| 2018-06-30 | AU$42.90 Million ≈ $30.36 Million |
+49.98% |
| 2017-06-30 | AU$28.61 Million ≈ $20.24 Million |
+42.05% |
| 2016-06-30 | AU$20.14 Million ≈ $14.25 Million |
+47.60% |
| 2015-06-30 | AU$13.64 Million ≈ $9.65 Million |
-20.46% |
| 2014-06-30 | AU$17.15 Million ≈ $12.14 Million |
+8.47% |
| 2013-06-30 | AU$15.81 Million ≈ $11.19 Million |
-1.13% |
| 2012-06-30 | AU$16.00 Million ≈ $11.32 Million |
-20.68% |
| 2011-06-30 | AU$20.17 Million ≈ $14.27 Million |
-31.66% |
| 2010-06-30 | AU$29.51 Million ≈ $20.88 Million |
-29.09% |
| 2009-06-30 | AU$41.61 Million ≈ $29.44 Million |
-24.30% |
| 2008-06-30 | AU$54.97 Million ≈ $38.90 Million |
-18.95% |
| 2007-06-30 | AU$67.82 Million ≈ $47.99 Million |
+297.31% |
| 2006-06-30 | AU$17.07 Million ≈ $12.08 Million |
+69.76% |
| 2005-06-30 | AU$10.06 Million ≈ $7.12 Million |
-1.87% |
| 2004-06-30 | AU$10.25 Million ≈ $7.25 Million |
+27.04% |
| 2003-06-30 | AU$8.07 Million ≈ $5.71 Million |
-23.33% |
| 2002-06-30 | AU$10.52 Million ≈ $7.44 Million |
-23.59% |
| 2001-06-30 | AU$13.77 Million ≈ $9.74 Million |
-10.83% |
| 2000-06-30 | AU$15.44 Million ≈ $10.93 Million |
-- |
About Clinuvel Pharmaceuticals Ltd
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with e… Read more